{
    "eid": "2-s2.0-85055966450",
    "title": "Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women",
    "cover-date": "2018-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "HIV",
        "INSTI",
        "TAF",
        "Tenofovir",
        "Women"
    ],
    "authors": [
        "Sally Hodder",
        "Kathleen Squires",
        "Cissy Kityo",
        "Debbie Hagins",
        "Anchalee Avihingsanon",
        "Anna Kido",
        "Shuping Jiang",
        "Rima Kulkarni",
        "Andrew Cheng",
        "Huyen Cao"
    ],
    "citedby-count": 14,
    "ref-count": 19,
    "ref-list": [
        "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel",
        "Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials",
        "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, noninferiority study",
        "Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial",
        "Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study",
        "A meta-analysis to assess the FDA DAVP\u2019s TLOVR algorithm in HIV submissions",
        "Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study",
        "Bone mineral density changes during the menopause transition in a multiethnic cohort of women",
        "Tenofovir-associated kidney toxicity in HIV-infected patients",
        "Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up",
        "Progressive renal tubular dysfunction associated with long-term use of tenofovir DF",
        "Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America",
        "The lipid-lowering effect of tenofovir/emtricitabine: a randomized, cross-over, double-blind, placebo-controlled trial",
        "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206",
        "Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care",
        "Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention"
    ],
    "affiliation": [
        {
            "affiliation-city": "Kampala",
            "@id": "60071691",
            "affilname": "Joint Clinical Research Center Uganda",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691",
            "affiliation-country": "Uganda"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60031780",
            "affilname": "Thai Red Cross Agency",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031780",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Morgantown",
            "@id": "60028124",
            "affilname": "WVU Health Sciences Center Morgantown",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028124",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Philadelphia",
            "@id": "60015277",
            "affilname": "Thomas Jefferson University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015277",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Foster City",
            "@id": "60002909",
            "affilname": "Gilead Sciences Incorporated",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Savannah",
            "@id": "113700425",
            "affilname": "Chatham Care Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113700425",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}